IS ONCOLOGY DRUG FINANCIAL TOXICITY A SPECIFIC US ISSUE?
Author(s)
Chouaid C1, Rémuzat C2, Caban A3, Toumi M4
1Centre Hospitalier Intercommunal, DHU-ATVB, Créteil, France, 2Creativ-Ceutical, Paris, France, 3Creativ-Ceutical, Krakow, Poland, 4Université Aix Marseilles, Marseilles, France
BACKGROUND: Cancer imposes enormous financial burden to society. Direct medical costs were estimated at around €51 billion across European (EU) countries (2009) and $88.7 billion in the United-States (US) (2011). The concept of “financial toxicity” has been first reported by US academic oncologists, Zafar and Abernathy in 2013. It refers to financial distress linked to out-of-pocket payments of costly oncology drugs (OD). This critical concept led to the development of a patient-reported outcome questionnaire by de Souza et al
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PHP340
Topic
Health Policy & Regulatory
Disease
Oncology